BPC-157: First Human Intravenous Safety Data Published in 2025 Pilot Study

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a segment of human gastric juice protein. Over the past two decades, it has accumulated a substantial body of preclinical literature suggesting cytoprotective, anti-inflammatory, and wound-healing properties across multiple organ systems. Despite this volume of animal data, human safety data for BPC-157 has remained virtually nonexistent — until now.

In early 2025, researchers published the first IRB-approved pilot safety study of intravenous BPC-157 administration in humans, appearing in Alternative Therapies in Health and Medicine (PubMed ID: 40131143). The study enrolled two healthy adult volunteers at a single clinical site in Florida and administered escalating intravenous doses over a two-day protocol. While the results showed no measurable adverse effects, the study's extremely limited scope — two subjects, no control group, and a three-day observation window — makes any broad safety conclusions premature.

This article provides a detailed examination of the study design, its findings, the broader preclinical context, current regulatory status, and the critical limitations that must frame any interpretation of these initial results.

The pilot study was designed as a single-center, open-label safety evaluation with no placebo arm or blinding. Two healthy volunteers were enrolled: a 68-year-old woman and a 58-year-old man, both over the age of 40 and without significant comorbidities. The inclusion criteria specified general good health, though specific exclusion criteria were not detailed in the publication abstract.

The dosing protocol followed a two-day escalation schedule. On Day 1, each subject received 10 mg of BPC-157 administered as an intravenous infusion over approximately one hour. On Day 2, the dose was increased to 20 mg, again delivered intravenously over one hour. Day 3 consisted of a follow-up evaluation with no additional dosing. The BPC-157 used in the study was sourced from a US-based 503A compounding pharmacy, a detail relevant to quality assurance and regulatory context.

Primary safety endpoints included continuous vital sign monitoring (blood pressure, heart rate, respiratory rate, temperature, and oxygen saturation) and a comprehensive panel of laboratory biomarkers assessed at baseline and follow-up. The laboratory panel encompassed a complete metabolic panel (CMP), complete blood count (CBC), creatine phosphokinase (CPK), brain natriuretic peptide (BNP), thyroid-stimulating hormone (TSH), and C-reactive protein (CRP). Self-reported adverse events were also collected from both subjects.

Across both subjects and both dosing days, the study reported no clinically significant adverse events. Vital signs remained stable throughout the infusion periods and during the follow-up day. Neither subject self-reported any side effects, including headache, nausea, injection site reactions, or cardiovascular symptoms.

Laboratory findings were similarly unremarkable. Cardiac biomarkers (BNP and CPK) showed no clinically relevant elevations, suggesting no acute myocardial stress at the administered doses. Renal function markers, including serum creatinine and estimated glomerular filtration rate (eGFR), demonstrated no sustained alterations. Hepatic enzymes remained within normal limits, indicating no acute liver toxicity. Inflammatory markers (CRP) and thyroid function (TSH) were stable.

• No clinically significant changes in cardiac biomarkers (BNP, CPK)
• Renal function (creatinine, eGFR) remained stable with no sustained deviations
• Liver enzymes within normal reference ranges throughout the study period
• Vital signs (BP, HR, RR, SpO2, temperature) stable during and after infusions
• No self-reported adverse events from either subject
• Inflammatory marker (CRP) showed no elevation

The investigators concluded that intravenous BPC-157 at doses of 10 mg and 20 mg was "well tolerated" with "no measurable adverse effects" in this limited cohort. However, the authors themselves acknowledged the preliminary nature of these findings and the need for substantially larger studies.

The IV safety pilot exists within a broader landscape of BPC-157 research that remains overwhelmingly preclinical. A 2025 narrative review titled "Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing and Pain" synthesized the available literature and found consistent signals of enhanced healing in animal models — including accelerated collagen deposition, improved tendon-to-bone integration, anti-inflammatory modulation, and central nervous system protective effects.

On the human side, the evidence base is thin but suggestive. The narrative review identified a case series involving knee pain patients in which 14 of 16 subjects reported symptomatic relief following BPC-157 administration. A separate pilot study in interstitial cystitis patients reported that 10 of 12 participants experienced complete symptom resolution. While these figures appear striking, both studies lacked randomization, blinding, and adequate controls — making them hypothesis-generating at best.

The review concluded that BPC-157 represents a "promising regenerative peptide" but explicitly stated that larger randomized controlled trials (RCTs) are required before any clinical conclusions can be drawn. Notably, no long-term safety data exists in humans, and no systematic assessment of cancer risk or immunological effects has been conducted in any species.

The regulatory landscape for BPC-157 remains contentious and rapidly evolving. The US Food and Drug Administration (FDA) has placed BPC-157 on its list of bulk drug substances that raise safety concerns when used in compounding. This designation reflects the agency's assessment that insufficient safety data exists to support the compound's use in compounded preparations for human administration.

This regulatory action has triggered legal disputes. Most notably, Evexias Health Solutions has filed legal challenges against the FDA's classification, arguing that the available evidence does not support placing BPC-157 in the category of substances with demonstrated safety risks. The outcome of these proceedings could significantly influence the future availability of compounded BPC-157 products in the United States.

It is important to note that BPC-157 is not an FDA-approved drug for any indication. The compound is not available as a registered pharmaceutical product, and its use in clinical settings currently occurs primarily through compounding pharmacies operating under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. The regulatory uncertainty surrounding its status adds an additional layer of complexity to interpreting any clinical data.

While the absence of adverse events in this pilot is a necessary first step, it is critical to enumerate what this study cannot demonstrate. The limitations are substantial and must be considered by any researcher evaluating this data.

• Sample size of n=2 provides no statistical power to detect adverse events, even those occurring at relatively high frequencies. An adverse event with a 20% incidence rate has a roughly 64% probability of being missed entirely in a two-person cohort.
• The absence of a placebo control group means no baseline comparison exists for observed biomarker fluctuations, however minor.
• A three-day observation window is wholly insufficient to detect delayed toxicity, cumulative effects, immunological reactions, or organ-specific damage that may emerge over weeks or months.
• The open-label design introduces expectation bias in self-reported outcome measures.
• No pharmacokinetic data were reported — serum BPC-157 concentrations, half-life, distribution, and clearance remain unknown for the IV route in humans.
• The source material from a 503A compounding pharmacy, while regulated, does not undergo the same level of quality assurance as an FDA-approved drug product.
• Potential conflicts of interest were not fully disclosed in the abstract, and the relationship between investigators and compounding entities warrants scrutiny.

In summary, this study demonstrates that two individuals tolerated two IV doses of BPC-157 without immediately observable harm. It does not demonstrate that BPC-157 is safe for intravenous use in the general population, at any dose, for any duration.

Despite its limitations, this pilot study serves an important function in the trajectory of BPC-157 research. It provides a published, IRB-approved precedent for human IV administration and establishes a preliminary dosing range (10–20 mg) that did not produce acute toxicity. For researchers designing subsequent trials, this data point — however limited — offers a starting reference for dose selection and safety monitoring protocols.

The logical next steps for the field include dose-escalation studies with larger cohorts (minimum 20–30 subjects), randomized placebo-controlled designs, extended follow-up periods of at least 30–90 days, pharmacokinetic profiling, and systematic documentation of potential conflicts of interest. Until such studies are completed and replicated, the safety profile of IV BPC-157 in humans remains fundamentally undefined.

The scientific community should approach BPC-157 with the rigor it applies to any novel therapeutic candidate: preclinical promise is not clinical proof, and a two-person pilot is the beginning of the evidence-gathering process, not its conclusion.

The primary endpoint was short-term safety and tolerability of intravenous BPC-157 administration in healthy volunteers, assessed through adverse event monitoring, vital signs, and laboratory parameters.

The pilot study enrolled a small cohort of healthy volunteers across multiple ascending dose groups. The exact enrollment numbers are detailed in the published protocol, but the limited sample size is acknowledged as a key limitation.

No. A single pilot study with limited participants and short follow-up cannot establish clinical safety. Phase II and Phase III trials with larger populations, longer observation periods, and placebo controls are required before any clinical safety determination.

This represents the first published human intravenous administration data. Prior research was limited to animal models and anecdotal reports. The transition from preclinical to human data marks a significant milestone in BPC-157 translational research.

The published study indicates that follow-up investigations are under consideration, though no registered Phase II trials have been publicly listed as of the publication date. Researchers should monitor clinical trial registries for updates.

The first human pilot study on intravenous BPC-157 administration (PubMed ID: 40131143) was published in 2025 and reported preliminary safety data. The study administered BPC-157 via intravenous infusion to a small cohort of human subjects. As a pilot study with limited sample size, the findings represent initial safety observations and require confirmation through larger, controlled clinical trials. The study noted that no serious adverse events were reported during the observation period, though the authors emphasized the preliminary nature of these findings. (Source: PubMed 40131143, 2025)

Explore detailed chemical profiles and research guides for compounds discussed in this article:

• BPC-157: Complete Research Guide → /learn/bpc-157

• Read more: RFK Jr. Signals Reversal of Peptide Ban: 14 of 19 Restricted Compounds May Return → https://www.chemverify.com/learn/rfk-jr-signals-reversal-of-peptide-ban-14-of-19-restricted-compounds-may-return
• Read more: AI-Guided High-Throughput Screening Accelerates Antimicrobial Peptide-Mimicking Polymer Discovery → https://www.chemverify.com/learn/ai-guided-antimicrobial-peptide-polymer-discovery
• Read more: Re-Engineering Insulin for Oral Delivery: Structural Modifications and Formulation Advances → https://www.chemverify.com/learn/insulin-oral-delivery-peptide-engineering
• Read more: Cyclic Lipopeptides: Biosurfactant Peptides as Next-Generation Drug Delivery Modulators → https://www.chemverify.com/learn/cyclic-lipopeptides-drug-delivery-modulators
• Read more: Microneedle-Delivered Peptide Decoy Receptors Show Promise in Psoriasis Treatment → https://www.chemverify.com/learn/microneedle-peptide-decoy-receptors-psoriasis